Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 14 ... as myeloproliferative disorders (MPDs). This group of diseases includes myelofibrosis, polycythemia vera and essential thrombocythemia. In addition, Cytopia has identified potential activity of ...
2009 NOV 16 ... Janus Kinase (JAK) Inhibitor Program INCB18424: (oral formulation) Myelofibrosis, Polycythemia Vera and Essential Thrombocythemia Continued patient enrollment of the Phase III ...
2009 AUG 24 ... to Dr. Izraeli, a similar mutation of the JAK2 in Down syndrome and leukemia causes Polycythemia Vera, a disease common in adults that leads to the overproduction of blood. This discovery of ...
2009 AUG 31 ... has been occasionally reported. The aim of this study, which included 353 patients with polycythemia vera and 467 with essential thrombocythemia, was to assess whether the risk of developing LPN ...
2009 AUG 31 ... (NIRCA),' is now available. "The screening for JAK2 V617F mutation in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis offers crucial information for ...
2009 OCT 12 ... According to a study from Toronto, Canada, "Polycythemia vera (PV) is a myeloproliferative disorder characterized by a pronounced increase in the ...
2009 SEP 7 ... an independent predictor of major thrombosis in both essential thrombocythemia (ET) and polycythemia vera (PV). However, whether leukocytosis should be simply considered a marker for vascular ...
2009 NOV 9 ... and management of the classic myeloproliferative disorders (MPDs), which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Nonetheless, ...
2009 AUG 24 ... According to recent research published in the International Journal of Hematology, "Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive ...
2009 AUG 24 ... of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients' new findings in enzyme research. "Somatic mutations in Janus kinase 2 ...
2009 AUG 31 ... modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a ...
2009 AUG 10 ... burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.' "Polycythemia vera (PV) is a clonal myeloproliferative neoplasia associated with the activation of the ...
2009 AUG 31 ... Genetics, Hematology, Myelofibrosis, Neoplasms, Oncology, Philadelphia Chromosome, Polycythemia Vera, Thrombocytosis, University of Cologne. This article was prepared by ...
2009 SEP 7 ... disorders (MPDs) we compared molecular changes in neutrophils from patients with polycythemia vera (PV) and essential thrombocythosis (ET), to neutrophils stimulated by GCSF ...
2009 OCT 12 ... with the JAK2V617F mutation in both retrovirally transfected fetal liver cells and polycythemia vera patients. Knockdown and overexpression studies in a well-characterized erythroid ...
2009 OCT 12 ... were mainly observed (10 of 12) in patients with primary myelofibrosis or patients with polycythemia vera or essential thrombocythemia who secondarily evolved toward myelofibrosis or acute ...
2009 NOV 9 ... from neutrophils of 10 of 11 ET patients studied using RED compared with 0 of 5 with polycythemia vera. These results were confirmed in cloned products from 5 ET patients and indicate the ...
2009 SEP 21 ... a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34(+) cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells ...
2009 NOV 2 ... There are no currently approved specific therapies for myelofibrosis (MF), polycythemia vera (PV), or essential thrombocythemia (ET), which collectively constitute the major ...
